Key Takeaways
- Two Approvals, One Appointment: An infusion center needs the drug authorized and the site of care authorized. A gap in either one holds the infusion chair, so both have to move at once.
- Site of Care Is a Separate Review: Payers assess the setting on its own inside precertification, and approving the drug does not answer the site question. A center that checks only drug coverage is half-verified.
- Lower-Acuity Settings Win Coverage: Payers steer specialty infusions toward the least intensive safe setting. Freestanding infusion suites, the office, and in-network home infusion are generally favored, while hospital outpatient draws the most scrutiny.
- The Drug Track Has Hard Gates: The GI biologic authorization itself carries strict criteria, a qualifying diagnosis backed by objective evidence, a documented history of conventional therapy, and a gastroenterologist’s involvement, so the clinical package has to match the payer’s exact rules.
- Most Chair Gaps Are Self-Inflicted: The common delays come from running the two approvals in sequence rather than together. The clinical facts usually exist; the workflow just is not built for two tracks.
When a GI biologic is infused in your center, you are asking the payer to approve two things, not one. The drug has to clear prior authorization, and so does the place it will be given. That second approval catches infusion centers off guard, because a clean drug authorization does nothing for the site-of-care question sitting right beside it. Miss either track and the infusion chair stays empty on the day you booked it.
This is what makes prior authorization for GI biologics in an infusion setting its own discipline. Payers increasingly run a site-of-care review alongside the drug review, and the two move on separate clocks. Crohn’s disease and ulcerative colitis patients cannot start or stay on therapy until both land.
The centers that fast-track these approvals share one habit. They start both tracks from the same intake and carry them forward together, so the drug clears and the site clears close enough in time to protect the schedule. This post breaks down the two tracks, where they stall, and how to run them in parallel. If your biologic infusions keep waiting on a late approval, start here.
The Two Authorization Tracks, and Where They Break Down
Start with the two tracks themselves, since naming them is the first step to running them together.
The drug track is the familiar one. It follows the standard GI biologic PA process: a qualifying diagnosis backed by objective evidence, a documented history of conventional therapy, and the payer’s medical necessity criteria, with a gastroenterologist prescribing or consulting. Payers commonly steer to a preferred product within the class, so the covered biologic may not be the one first written, and these approvals are usually time-limited, which puts reauthorization on the calendar from the start.
The site-of-care track is the one centers underestimate. Here the payer asks a different question: is this the right setting for the infusion, or would a lower-acuity site serve. The direction of that question surprises people. Payers push toward the least intensive safe setting, and a freestanding infusion suite, the office, or in-network home infusion usually sits on the favored side. Independence Blue Cross, for instance, names the office, home infusion, and an ambulatory freestanding infusion suite as its cost-effective settings, with hospital outpatient the setting that has to be justified. Where a higher-acuity setting is genuinely needed, the justification has to be clinical. Aetna’s site-of-care policy allows the more intensive setting for reasons like an unstable cardiopulmonary or kidney condition, a history of serious infusion reactions or anti-drug antibodies, or vein access that needs special handling.
Three breakdowns account for most of the delay. The site-of-care request goes in after the drug PA rather than next to it, which opens a gap between drug approval and a scheduled infusion. The medical necessity documentation gets built for the drug and never tailored to the setting. And benefit verification confirms the drug is covered while the site-of-care coverage question goes unasked. Every one of these is a sequencing problem in the workflow, because the clinical facts the payer wants are already in the record.
Is Your Authorization Package Complete? A Pre-Submission Checklist
Catching these gaps before a submission goes out beats unwinding a denial after it comes back. Run the package against this pre-submission check, which covers both tracks in one pass.
| Checklist item | What to verify or document |
|---|---|
| Confirmed GI diagnosis | Objective evidence for the condition, endoscopic, histologic, or imaging findings with dates, not a diagnosis code on its own |
| Prior therapy history | Documented failure, intolerance, or contraindication for each required prior therapy, with drug, duration, dosing, and response data |
| Payer-required labs | Any baseline or safety labs the specific payer requires for the requested biologic |
| Site-of-care justification | Confirmation that the infusion setting matches the payer’s cost-effective-setting rules, with clinical rationale on file if a higher-acuity setting is needed |
The first three rows carry the drug track. The fourth is the one a drug-only checklist leaves out, and it is the row most likely to hold the chair.
Building a Parallel-Track Workflow
A complete package is the input. A parallel-track workflow is what gets both approvals moving on it at once.
Three practices define it. The drug PA and the site-of-care PA both start from the same intake documentation, on the same day, rather than one waiting on the other. Benefit verification checks drug coverage and site-of-care coverage in a single pass, so the facility question is answered before a drug PA is already in flight. And the follow-up cadence tracks both authorizations against the scheduled infusion date, not just the payer’s standard turnaround window, with reauthorization planned ahead of the limit many policies set so a maintenance infusion never waits on a lapsed approval.
Running the two tracks together is the same work in a better order. It closes the gap between drug approval and a booked chair, which is where infusion centers lose time they cannot bill back.
Fast-Tracking Prior Authorization for GI Biologics in Infusion Centers
All of this ladders up to one operational fact. An empty infusion chair is revenue the day cannot recover, and most of those gaps trace to a PA process built for one track instead of two. Close the distance between drug approval and site approval, and the schedule holds.
That is the problem CareTria Provider Connect is built to solve for infusion centers. It handles medical and pharmacy benefit authorization in one workflow, which maps onto the parallel-track requirement this post described, and it returns benefit investigations in real time, so the site-of-care coverage question gets answered at intake rather than after a drug PA is already moving.
See how CareTria Provider Connect manages both authorization tracks for GI infusion centers. Explore Provider Connect.
Why does an infusion center need two authorizations for one GI biologic?
Because the payer approves the drug and the setting separately. The drug track confirms the biologic is medically necessary for the patient. The site-of-care track confirms the infusion belongs in the chosen setting rather than a lower-acuity one. Both have to clear before the infusion can be billed and given.
What is site-of-care authorization?
It is a payer review of where an infusion will be administered, run as part of precertification. Payers favor the least intensive safe setting, so a freestanding infusion suite, the office, or home infusion is often accepted readily, while a hospital outpatient setting usually needs clinical justification.
Does approving the drug mean the infusion site is approved too?
No. A drug authorization and a site-of-care authorization are distinct decisions. A biologic can be fully approved while the site-of-care question is still open, which is exactly the gap that leaves a scheduled chair empty.
What makes a GI biologic drug authorization strong?
Objective evidence of the diagnosis, a documented prior-therapy history with duration, dosing, and response for each required treatment, any payer-specific labs, and involvement of a gastroenterologist. Building that package to the specific payer’s criteria is what clears the drug track on the first pass.
How do infusion centers prevent gaps between approval and infusion?
By starting the drug PA and the site-of-care PA together from the same intake, verifying drug and site coverage in one check, and tracking both approvals against the scheduled infusion date rather than the payer’s generic turnaround.
